Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose‑ranging study of LY3009104 in moderate-to-severe plaque psoriasis
jRCT2080221828Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of baricitinib in plaque psoriasis (5 arms), sponsored by Eli Lilly and Company. Started Jun 2012; status: completed.
02
Drugs
baricitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2080221828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221828.